Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55 Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed

被引：0
|
作者：
Eriksson, Pontus [1 ]
Sjodahl, Gottfrid [2 ]
Liedberg, Fredrik [2 ]
机构：
[1] Lund Univ, Lund Univ Hosp, Dept Clin Sci, Div Oncol & Pathol, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Translat Med, SE-20502 Malmo, Sweden
来源：
EUROPEAN UROLOGY | 2017年 / 72卷 / 05期
关键词：
EXPRESSION; HER2;
D O I：
10.1016/j.eururo.2017.05.027
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E135 / E136
页数：2
相关论文
共 4 条
  • [1] Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?
    Powles, Thomas
    de Liano, Alfonso Gomez
    Ackerman, Charlotte
    EUROPEAN UROLOGY, 2017, 72 (05) : E137 - E138
  • [2] Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
    Powles, Thomas
    Huddart, Robert A.
    Elliott, Tony
    Sarker, Shah-Jalal
    Ackerman, Charlotte
    Jones, Robert
    Hussain, Syed
    Crabb, Simon
    Jagdev, Satinder
    Chester, John
    Hilman, Serena
    Beresford, Mark
    Macdonald, Graham
    Santhanam, Sundar
    Frew, John A.
    Stockdale, Andrew
    Hughes, Simon
    Berney, Daniel
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 48 - +
  • [3] Re: Phase III, Double-Blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-Line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer Editorial Comment
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2018, 199 (04): : 891 - 891
  • [4] A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients
    Powles, Thomas
    Huddart, Robert Anthony
    Elliott, Tony
    Jones, Robert
    Hussain, Syed A.
    Crabb, Simon J.
    Ackerman, Charlotte
    Jagdev, Satinder
    Chester, John D.
    Hilman, Serena
    Beresford, Mark
    Macdonald, A. Graham
    Sundar, Santhanam
    Frew, John A.
    Stockdale, Andrew
    Sarker, Shah-Jalal
    Berney, Daniel
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1